Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Autoimmune Liver Disease
What is your approach to treatment of immune-mediated overlap syndromes, such as AIH-PBC?
Related Questions
In what clinical scenario do you initiate the use of ileal bile acid transport (IBAT) inhibitors in the management of cholestatic liver disease?
How will the recent withdrawal of Ocaliva for the treatment of PBC impact your therapeutic and management plan for these patients?
What early response criteria and timeframe do you use to declare corticosteroid non-response and move to expedited transplant listing in patient with acute severe AIH without encephalopathy?
What patient factors guide your selection of maintenance therapies for a patient with autoimmune hepatitis?
For suspected drug-induced autoimmune-like hepatitis after the culprit drug is stopped and there is no advanced fibrosis, how do you decide immunosuppression duration and the relapse-free follow-up interval needed to confidently label it DI-ALH rather than classic AIH?
How do you prefer to manage IgG-4 related hepato-biliary disease, especially if there are similarities in imaging findings to other immune mediated liver diseases?
In what clinical scenario would you consider the use of budesonide over prednisone as part of the pharmacologic management of autoimmune hepatitis?
How do you approach restarting immunotherapy in a patient with metastatic melanoma who previously developed immune-mediated hepatitis (Grade 3), with liver enzymes now back to baseline levels?
What is your strategy to manage pruritus in patients with cholestatic liver disease?
In AIH/PBC overlap with both hepatitis and cholestasis, how do you determine whether incomplete biochemical response at 6–12 months reflects undertreated AIH versus inadequately controlled cholestasis?
